MK3475-B61 - A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)

  • Gurney, Howard (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Tan, Pearlyn (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymKeynote B61
StatusActive
Effective start/end date1/02/21 → 10/12/25
View all
View less